Standardizing CAR-T therapy: Getting it scaled up
X Dai, Y Mei, D Cai, W Han - Biotechnology advances, 2019 - Elsevier
X Dai, Y Mei, D Cai, W Han
Biotechnology advances, 2019•ElsevierCAR-T therapy, grafting the specificity of a monoclonal antibody onto a T cell to target certain
cancer cells, has been recognized as a promising therapeutic approach for cancer control
as evidenced by the two CAR-T products proved by FDA in 2017. However, the unique
heterogeneity of CAR-T therapy has restricted its production in a limited number of
institutions and made it a boutique oncotherapy. By reviewing outstanding issues
surrounding the commercial scale production of CAR-T therapy, we conclude that achieving …
cancer cells, has been recognized as a promising therapeutic approach for cancer control
as evidenced by the two CAR-T products proved by FDA in 2017. However, the unique
heterogeneity of CAR-T therapy has restricted its production in a limited number of
institutions and made it a boutique oncotherapy. By reviewing outstanding issues
surrounding the commercial scale production of CAR-T therapy, we conclude that achieving …
Abstract
CAR-T therapy, grafting the specificity of a monoclonal antibody onto a T cell to target certain cancer cells, has been recognized as a promising therapeutic approach for cancer control as evidenced by the two CAR-T products proved by FDA in 2017. However, the unique heterogeneity of CAR-T therapy has restricted its production in a limited number of institutions and made it a boutique oncotherapy. By reviewing outstanding issues surrounding the commercial scale production of CAR-T therapy, we conclude that achieving mass production of CAR-T therapy without sacrificing its personalized nature is a worldwild challenge for making CAR-T a key element in the next generation of precision medicine, which can be achieved by standardizing 7 prominent factors that collectively determine the scale of CAR-T manufacturing.
Elsevier